[Skip to Navigation]
September 13, 2021

US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?

Author Affiliations
  • 1University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France
  • 2Centre Mémoire Ressources Recherches, Pôle de Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France
  • 3AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Department of Neurology, Institute of Memory and Alzheimer’s Disease, Paris, France
  • 4Institut du Cerveau - ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
JAMA Neurol. 2021;78(11):1307-1308. doi:10.1001/jamaneurol.2021.3126

On June 7, 2021, the US Food and Drug Administration (FDA) publicly announced that it would grant accelerated approval for aducanumab in patients with Alzheimer disease (AD) based on the “evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients.”1 To our knowledge, for the first time in the field of AD, a government agency has used a surrogate end point for drug approval, ie, an end point “that is thought to predict clinical benefit but is not itself a measure of clinical benefit.”1 The FDA considered reduction of amyloid load, as measured with amyloid positron emission tomography (PET), to be a valid surrogate end point of clinical benefit in AD. This position is unprecedented and raises numerous controversies.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words